Cochrane · systematic review · CD010219
Selective noradrenaline reuptake inhibitors for schizophrenia
Matthews, PRL, Horder, J, Pearce, M · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
1
Included studies
NR
No studies 1 · 14.3%Ungraded 0 · 0%Very low 3 · 42.9%Low 3 · 42.9%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Noradrenaline reuptake inhibitors versus placebo
Population: adults with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mental state: significant response or improvement in negative symptoms (PANSS negative subscale, high = worse) ‐ short term (12 weeks) Noradrenaline reuptake inhibitors vs placebo | RR 3.17 [1.52, 6.58] | 1 study · 50 participants | Very low Downgraded: imprecision |
Mental state: specific ‐ average positive symptoms score (PANSS positive subscale, high = worse) ‐ short term (2 to 12 weeks) Noradrenaline reuptake inhibitors vs placebo | no estimate extracted | 5 studies · 294 participants | Low Downgraded: imprecision |
Clinical global response: significant response or improvement in global status (CGI‐S, high = worse) ‐ short term (4 weeks) Noradrenaline reuptake inhibitors vs placebo | RR 0.99 [0.45, 2.2] | 1 study · 28 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Cognitive functioning: significant response or improvement in cognitive functioning Noradrenaline reuptake inhibitors vs placebo | no estimate extracted | NR | No studies |
Cognitive functioning: average compostive endpoint score (SMD, low = favours NRI) ‐ short term (2 to 12 weeks) Noradrenaline reuptake inhibitors vs placebo | no estimate extracted | 4 studies · 180 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |
Quality of life: Average endpoint score (GQOLI‐74, high = better) ‐ short term (2 to 12 weeks) Noradrenaline reuptake inhibitors vs placebo | no estimate extracted | 1 study · 114 participants | Very low Downgraded: imprecision |
Adverse effects: Nausea ‐ short term (2 to 12 weeks) Noradrenaline reuptake inhibitors vs placebo | RR 0.49 [0.1, 2.41] | 3 studies · 176 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness, publication bias |